This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
General Electric (GE) Q1 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
General Electric's (GE) first-quarter 2019 results decline year over year due to weak sales performance and fall in margins. However, results surpass estimates.
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
Top Research Reports for Roche, Danaher & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Roche (RHHBY), Danaher (DHR) and BlackRock (BLK).
Honeywell (HON) Q1 Earnings & Revenues Outpace Estimates
by Zacks Equity Research
Solid long-cycle businesses in U.S. defense, commercial aerospace, and warehouse and process automation drive Honeywell's (HON) Q1.
Danaher (DHR) Q1 Earnings Top, View Down on Buyout Impact
by Zacks Equity Research
Danaher's (DHR) first-quarter 2019 results gain from sales growth and DBS initiatives. It lowers projection for 2019 to include the dilutive impact of the BioPharma buyout.
Danaher (DHR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Danaher's (DHR) first-quarter 2019 results to gain from solid product portfolio, innovative capabilities, Danaher Business System and acquired assets. Forex woes, tariffs and high costs drag.
Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Analyst Reports for Mastercard, Honeywell & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Honeywell (HON) and Thermo Fisher (TMO).
UTX or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
UTX vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
Danaher to Gain From Solid Demand in Key Markets Amid Risks
by Zacks Equity Research
Effective implementation of Danaher Business System and solid demand for innovative products are likely to boost Danaher's (DHR) revenues.
Danaher's Stock Offering Proceeds to Fund BioPharma Buyout
by Zacks Equity Research
Danaher (DHR) successfully completes the offering of common and preferred shares. It intends on using the funds raised to pay for the pending acquisition of General Electric's BioPharma business.
GE Intends to Lower Debt Burden, Boost Dividend Payments
by Zacks Equity Research
General Electric (GE) seeks to become more competent on the back of its initiatives to improve financial position and strengthen core businesses.
Danaher to Buy BioPharma, Offers Common & Preferred Shares
by Zacks Equity Research
Danaher (DHR) to gain from the buyout of the BioPharma business. This is likely to strengthen its biologics workflow solutions business. The company offers common and preferred shares.
General Electric (GE) to Divest BioPharma, Closes Wabtec Deal
by Zacks Equity Research
General Electric (GE) to gain from divestiture of the BioPharma business by using the proceeds to lower debt burden and focus on more important portfolios. It completes GE Transportation divestment.
Company News For Feb 26, 2019
by Zacks Equity Research
Companies In The News Are: DHR,GE,ONCE,CMTA,CRI
Danaher (DHR) Catches Eye: Stock Jumps 8.5%
by Zacks Equity Research
Danaher (DHR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pre-Markets Up, GE Sells Off Biopharma Biz
by Mark Vickery
With President Trump again delaying the 25% tariff rate and GE raising over $21 billion to pay down debt, futures are in the green this morning.
Positive Development on Trade War Front
by Zacks Equity Research
Positive Development on Trade War Front
Pre-Markets Up, GE Sells Off Biopharma Biz
by Mark Vickery
With President Trump again delaying the 25% tariff rate and GE raising over $21 billion to pay down debt, futures are in the green this morning.
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
Top Research Reports for ExxonMobil, Merck & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Merck (MRK) and Danaher (DHR).
CSL or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CSL vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Danaher's (DHR) Q4 earnings jump year over year on the back of solid performance across all its segments.
Danaher (DHR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 0.79% and 0.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?